<DOC>
	<DOCNO>NCT00342940</DOCNO>
	<brief_summary>The present study aim evaluate safety immunogenicity one dose commercially available Surface Antigen , Inactivated Influenza Vaccine , Formulation 2006-2007 , non-elderly adult elderly subject .</brief_summary>
	<brief_title>Safety Immunogenicity Commercially Available Influenza Vaccine ( Formulation 2006/2007 ) When Administered Subjects 18 Years Age Older</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject 18 year age old autoimmune disease serious acute , chronic progressive disease hypersensitivity egg , chicken protein , chicken feather , influenza viral protein , neomycin polymyxin component vaccine know suspect ( high risk develop ) impairment/alteration immune function within past 7 day acute disease infection require systemic antibiotic antiviral therapy history neurological symptom sign , anaphylactic shock follow administration vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>influenza</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>flu</keyword>
	<keyword>vaccination</keyword>
	<keyword>immunogenicity</keyword>
</DOC>